Journey Medical (NASDAQ:DERM) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Journey Medical (NASDAQ:DERM) in a research note issued to investors on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $13.00 price objective on the stock. HC Wainwright also issued estimates for Journey Medical’s Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.31 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.15 EPS.

Other equities analysts have also recently issued reports about the company. Zacks Research cut Journey Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 15th. Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research report on Thursday, May 15th. Wall Street Zen cut Journey Medical from a “buy” rating to a “hold” rating in a research report on Sunday, July 6th. Finally, Lake Street Capital lifted their price target on Journey Medical from $9.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Journey Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.17.

Journey Medical Price Performance

Shares of NASDAQ DERM opened at $7.48 on Monday. The stock has a market cap of $182.36 million, a PE ratio of -19.68 and a beta of 0.80. Journey Medical has a fifty-two week low of $3.54 and a fifty-two week high of $8.90. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.95 and a current ratio of 1.27. The stock has a fifty day moving average of $7.22 and a 200-day moving average of $6.64.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The company had revenue of $15.01 million during the quarter, compared to analysts’ expectations of $14.93 million. Journey Medical had a negative net margin of 15.49% and a negative return on equity of 48.69%. Equities research analysts anticipate that Journey Medical will post -1.02 earnings per share for the current year.

Institutional Investors Weigh In On Journey Medical

Several large investors have recently added to or reduced their stakes in DERM. Police & Firemen s Retirement System of New Jersey bought a new stake in Journey Medical during the second quarter valued at $29,000. Bank of America Corp DE lifted its stake in Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Journey Medical during the second quarter worth about $36,000. JPMorgan Chase & Co. bought a new stake in Journey Medical during the second quarter worth about $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Journey Medical during the second quarter worth about $48,000. Institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.